← Back to Search

Other

Self-Administered Glucose Test for Postpartum Diabetes Screening

N/A

Recruiting

Led By Amy Crockett, MD

Research Sponsored by Prisma Health-Upstate

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Capable of providing informed consent

No personal history of Type 1 or Type 2 diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 12 weeks of delivery

Awards & highlights

Study Summary

This trial looks at whether self-testing for diabetes after giving birth increases screening completion rates.

Who is the study for?

This trial is for women over 18 who had gestational diabetes during pregnancy, delivered at Greenville Memorial Hospital, and are recommended for postpartum diabetes screening. They must be able to consent, use Prisma Health's MyChart system in English or Spanish, and perform fingerstick glucose monitoring.Check my eligibility

What is being tested?

The study tests if a self-administered oral glucose tolerance test with virtual follow-up can increase the rate of postpartum diabetes screening within 12 weeks after giving birth compared to standard methods.See study design

What are the potential side effects?

Since this trial involves a standard glucose tolerance test that patients administer themselves, side effects may include discomfort from finger pricks for blood sampling and potential anxiety or stress related to self-testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I understand the study and can agree to participate.

Select...

I have never been diagnosed with Type 1 or Type 2 diabetes.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 12 weeks of delivery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 12 weeks of delivery

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 12 weeks of delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Completion of 75-gram oral glucose tolerance test

Secondary outcome measures

Attendance at routine postpartum visit

Other outcome measures

Patient satisfaction

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Self-administered diabetes screenExperimental Treatment1 Intervention

Self-administered 75-gram oral glucose tolerance test with 4-week virtual follow-up visit. Drug: GlucoCrush

Group II: Routine postpartum careActive Control1 Intervention

Office based oral glucose tolerance test at 6 weeks postpartum, per normal protocol. Drug: GlucoCrush

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Prisma Health-UpstateLead Sponsor

83 Previous Clinical Trials

42,828 Total Patients Enrolled

Amy Crockett, MDPrincipal InvestigatorPrisma Health-Upstate

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are taking part in this experiment?

"Affirmative. Per the information published on clinicaltrials.gov, this medical study is currently in recruitment mode and was initially posted on November 2nd 2023. The trial has a goal of recruiting 200 individuals from one centre."

Answered by AI

Are there still available slots in this research project for volunteers?

"Affirmative. According to the clinicaltrials.gov portal, this investigation is actively enrolling participants; it was first posted on November 2nd 2023 and last modified on November 13th 2023. This trial requires 200 individuals from one site for completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Self-Administered 2-Hour Oral Glucose Tolerance Test

2023. "Self-Administered 2-Hour Oral Glucose Tolerance Test". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06099509.